BPAi

Bio-Path AI (BPAI) is a biotechnology subsidiary of Bio-Path Holdings focused on integrating artificial intelligence and machine learning into the drug discovery and development process. The company leverages its parent company's proprietary DNAbilize antisense technology platform to identify and optimize novel therapeutic candidates for cancer and other challenging diseases. By utilizing AI-driven predictive modeling, Bio-Path AI aims to accelerate the identification of high-value targets and improve the precision of its RNA-based therapeutic pipeline. The company's primary focus is on developing targeted treatments for hematological malignancies and solid tumors where traditional therapies have failed. Bio-Path AI represents a strategic expansion into digital biology to enhance the efficiency and success rate of its clinical programs.